Questions Overshadow Roche’s Bid To Make Tecentriq First Adjuvant Liver Cancer Treatment
Company Will Need More Data To File
Despite recording the first success for an adjuvant drug therapy in hepatocellular carcinoma, Roche is likely to need longer-term safety and efficacy data before attempting a filing.
